Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-08-13

AUTHORS

Antonio Nicolucci, Riccardo Candido, Domenico Cucinotta, Giusi Graziano, Alberto Rocca, Maria C. Rossi, Franco Tuccinardi, Valeria Manicardi

ABSTRACT

IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4–6.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca. More... »

PAGES

2895-2909

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z

DOI

http://dx.doi.org/10.1007/s12325-019-01043-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1120311915

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31410779


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Canagliflozin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicolucci", 
        "givenName": "Antonio", 
        "id": "sg:person.01112613263.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112613263.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.460062.6", 
          "name": [
            "Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Candido", 
        "givenName": "Riccardo", 
        "id": "sg:person.01026702544.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 di Messina, Messina, Italy", 
          "id": "http://www.grid.ac/institutes/grid.10438.3e", 
          "name": [
            "Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 di Messina, Messina, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cucinotta", 
        "givenName": "Domenico", 
        "id": "sg:person.01232501740.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232501740.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graziano", 
        "givenName": "Giusi", 
        "id": "sg:person.0637110453.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637110453.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Struttura Semplice Diabetologia e Malattie Metaboliche \u201cGiovanni Segalini\u201d, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414266.3", 
          "name": [
            "Struttura Semplice Diabetologia e Malattie Metaboliche \u201cGiovanni Segalini\u201d, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rocca", 
        "givenName": "Alberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossi", 
        "givenName": "Maria C.", 
        "id": "sg:person.010041300312.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010041300312.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tuccinardi", 
        "givenName": "Franco", 
        "id": "sg:person.010035354133.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035354133.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AMD Annals Coordinator, Reggio Emilia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AMD Annals Coordinator, Reggio Emilia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manicardi", 
        "givenName": "Valeria", 
        "id": "sg:person.0642244236.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642244236.63"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00125-019-4839-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112731482", 
          "https://doi.org/10.1007/s00125-019-4839-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-015-3547-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048430137", 
          "https://doi.org/10.1007/s00125-015-3547-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-014-0688-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027960230", 
          "https://doi.org/10.1007/s00592-014-0688-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-08-13", 
    "datePublishedReg": "2019-08-13", 
    "description": "IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4\u20136.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-019-01043-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "sodium-glucose cotransporter 2 inhibitors", 
      "EMPA-REG OUTCOME", 
      "eligibility criteria", 
      "eligible patients", 
      "safety trial", 
      "type 2 diabetes mellitus", 
      "Italian diabetes clinics", 
      "major eligibility criteria", 
      "cardiovascular safety trials", 
      "proportion of patients", 
      "percentage of patients", 
      "cotransporter 2 inhibitors", 
      "peripheral arterial disease", 
      "patient eligibility criteria", 
      "different eligibility criteria", 
      "cross-sectional study", 
      "VERTIS CV", 
      "microvascular complications", 
      "renal protection", 
      "primary endpoint", 
      "diabetes clinic", 
      "adult patients", 
      "diabetes mellitus", 
      "arterial disease", 
      "cerebrovascular disease", 
      "cardiovascular protection", 
      "SGLT2 inhibitors", 
      "lower BMI", 
      "patient population", 
      "novel agents", 
      "Drug Administration guidance", 
      "low prevalence", 
      "patients", 
      "US Food", 
      "clinical practice", 
      "older age", 
      "study design", 
      "trials", 
      "T2DM", 
      "Administration guidance", 
      "high rate", 
      "treatment", 
      "Italian adults", 
      "disease", 
      "current use", 
      "present study", 
      "outcomes", 
      "inhibitors", 
      "mellitus", 
      "MethodsThis", 
      "BMI", 
      "complications", 
      "ResultsAmong", 
      "clinic", 
      "population", 
      "criteria", 
      "prevalence", 
      "proportion", 
      "endpoint", 
      "study", 
      "adults", 
      "age", 
      "enrollment", 
      "generalizability", 
      "duration", 
      "protection", 
      "aim", 
      "agents", 
      "percentage", 
      "food", 
      "minority", 
      "levels", 
      "evaluation", 
      "number", 
      "rate", 
      "large number", 
      "guidance", 
      "use", 
      "practice", 
      "data", 
      "implications", 
      "definition", 
      "canvases", 
      "world", 
      "real world", 
      "similarity", 
      "terms", 
      "design", 
      "reflection", 
      "CVOTs", 
      "outcomes safety trials", 
      "generalizability of CVOTs", 
      "VERTIS-CV (ertugliflozin) studies"
    ], 
    "name": "Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice", 
    "pagination": "2895-2909", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1120311915"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-019-01043-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31410779"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-019-01043-z", 
      "https://app.dimensions.ai/details/publication/pub.1120311915"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_803.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-019-01043-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'


 

This table displays all metadata directly associated to this object as RDF triples.

292 TRIPLES      22 PREDICATES      138 URIs      127 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-019-01043-z schema:about N382632a75ed342ba9e74a21e87bd0c7e
2 N3baa2bdd3f0143a5bfd73a5eb8708ac8
3 N51f6a233cb974b1f99546bf5388b283e
4 N5b5bc49dd3ae4917842afba6a505847c
5 N66abf0dd5fcc42d1b7ccde0c1cd26058
6 N6bc3e70dcc8944d488a9674851169a5d
7 N77d427130c814119ab3c881444cc10bd
8 N7af9f5ffb64a4a9e9172eb11978ea739
9 N8684e3a3a7bf402ca04a1d89f281aa5a
10 Nb047513c4db24a8381e76e9fdf27120a
11 Nd5f88775f52f4ea49e723d606d871569
12 Ndcb5d6c3308c4a8bb66f93a9ad1d70cb
13 Neab540d5f2a14f49b97d0ccd94cf48e4
14 Necf4cb75a6c14ebba33146fc8f41ffd4
15 Nf316133483a245c89b661742d6c910f0
16 Nfb9f0d31f9b34c26a418d596f8c69a91
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N45d51b32905546c4a7325f02568ed752
20 schema:citation sg:pub.10.1007/s00125-015-3547-2
21 sg:pub.10.1007/s00125-019-4839-8
22 sg:pub.10.1007/s00592-014-0688-6
23 schema:datePublished 2019-08-13
24 schema:datePublishedReg 2019-08-13
25 schema:description IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4–6.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N43292c33ecdb4d9d81def06b1b05ff2e
30 N5ff1c87be9924c19a28227e236d25d8a
31 sg:journal.1096634
32 schema:keywords Administration guidance
33 BMI
34 CVOTs
35 Drug Administration guidance
36 EMPA-REG OUTCOME
37 Italian adults
38 Italian diabetes clinics
39 MethodsThis
40 ResultsAmong
41 SGLT2 inhibitors
42 T2DM
43 US Food
44 VERTIS CV
45 VERTIS-CV (ertugliflozin) studies
46 adult patients
47 adults
48 age
49 agents
50 aim
51 arterial disease
52 canvases
53 cardiovascular protection
54 cardiovascular safety trials
55 cerebrovascular disease
56 clinic
57 clinical practice
58 complications
59 cotransporter 2 inhibitors
60 criteria
61 cross-sectional study
62 current use
63 data
64 definition
65 design
66 diabetes clinic
67 diabetes mellitus
68 different eligibility criteria
69 disease
70 duration
71 eligibility criteria
72 eligible patients
73 endpoint
74 enrollment
75 evaluation
76 food
77 generalizability
78 generalizability of CVOTs
79 guidance
80 high rate
81 implications
82 inhibitors
83 large number
84 levels
85 low prevalence
86 lower BMI
87 major eligibility criteria
88 mellitus
89 microvascular complications
90 minority
91 novel agents
92 number
93 older age
94 outcomes
95 outcomes safety trials
96 patient eligibility criteria
97 patient population
98 patients
99 percentage
100 percentage of patients
101 peripheral arterial disease
102 population
103 practice
104 present study
105 prevalence
106 primary endpoint
107 proportion
108 proportion of patients
109 protection
110 rate
111 real world
112 reflection
113 renal protection
114 safety trial
115 similarity
116 sodium-glucose cotransporter 2 inhibitors
117 study
118 study design
119 terms
120 treatment
121 trials
122 type 2 diabetes mellitus
123 use
124 world
125 schema:name Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice
126 schema:pagination 2895-2909
127 schema:productId N4d0fcdb1aa404531b21c4a0a3e493f42
128 Na5dc66e0264c47809532dec4c18144a4
129 Nc3baebdd8085481b98bdba79bb172ba2
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120311915
131 https://doi.org/10.1007/s12325-019-01043-z
132 schema:sdDatePublished 2022-01-01T18:49
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N924308f86d4d43949c159b188bfac16c
135 schema:url https://doi.org/10.1007/s12325-019-01043-z
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N2ac6117b8679422fb8b713286a63d125 rdf:first sg:person.01026702544.26
140 rdf:rest Nf54c5648924d48c7952a5de2eae9129b
141 N382632a75ed342ba9e74a21e87bd0c7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Diabetes Mellitus, Type 2
143 rdf:type schema:DefinedTerm
144 N3baa2bdd3f0143a5bfd73a5eb8708ac8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N43292c33ecdb4d9d81def06b1b05ff2e schema:volumeNumber 36
148 rdf:type schema:PublicationVolume
149 N45d51b32905546c4a7325f02568ed752 rdf:first sg:person.01112613263.43
150 rdf:rest N2ac6117b8679422fb8b713286a63d125
151 N4d0fcdb1aa404531b21c4a0a3e493f42 schema:name pubmed_id
152 schema:value 31410779
153 rdf:type schema:PropertyValue
154 N4f577a16c95045d19fa5f2bb458d1437 rdf:first sg:person.0642244236.63
155 rdf:rest rdf:nil
156 N51f6a233cb974b1f99546bf5388b283e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Canagliflozin
158 rdf:type schema:DefinedTerm
159 N5b5bc49dd3ae4917842afba6a505847c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Aged, 80 and over
161 rdf:type schema:DefinedTerm
162 N5ff1c87be9924c19a28227e236d25d8a schema:issueNumber 10
163 rdf:type schema:PublicationIssue
164 N66abf0dd5fcc42d1b7ccde0c1cd26058 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 N6bc3e70dcc8944d488a9674851169a5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Glucosides
169 rdf:type schema:DefinedTerm
170 N77d427130c814119ab3c881444cc10bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cross-Sectional Studies
172 rdf:type schema:DefinedTerm
173 N7af9f5ffb64a4a9e9172eb11978ea739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name United States
175 rdf:type schema:DefinedTerm
176 N83cf8fdb7b6c4ad1941905346e29e079 rdf:first sg:person.0637110453.18
177 rdf:rest Ne461a95aa26041bfbee775a67d7e291b
178 N8684e3a3a7bf402ca04a1d89f281aa5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Sodium-Glucose Transporter 2
180 rdf:type schema:DefinedTerm
181 N924308f86d4d43949c159b188bfac16c schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 Na0c9f4743ad54dfda13aac1a99f87703 schema:affiliation grid-institutes:grid.414266.3
184 schema:familyName Rocca
185 schema:givenName Alberto
186 rdf:type schema:Person
187 Na5dc66e0264c47809532dec4c18144a4 schema:name dimensions_id
188 schema:value pub.1120311915
189 rdf:type schema:PropertyValue
190 Nb047513c4db24a8381e76e9fdf27120a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Cardiovascular Diseases
192 rdf:type schema:DefinedTerm
193 Nb236d04a466742c8bc3cd94ab0d626d7 rdf:first sg:person.010035354133.81
194 rdf:rest N4f577a16c95045d19fa5f2bb458d1437
195 Nc3baebdd8085481b98bdba79bb172ba2 schema:name doi
196 schema:value 10.1007/s12325-019-01043-z
197 rdf:type schema:PropertyValue
198 Ncaadd10e204c46ddb2c1287b06816dbc rdf:first sg:person.010041300312.03
199 rdf:rest Nb236d04a466742c8bc3cd94ab0d626d7
200 Nd5f88775f52f4ea49e723d606d871569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Benzhydryl Compounds
202 rdf:type schema:DefinedTerm
203 Ndcb5d6c3308c4a8bb66f93a9ad1d70cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Male
205 rdf:type schema:DefinedTerm
206 Ne461a95aa26041bfbee775a67d7e291b rdf:first Na0c9f4743ad54dfda13aac1a99f87703
207 rdf:rest Ncaadd10e204c46ddb2c1287b06816dbc
208 Neab540d5f2a14f49b97d0ccd94cf48e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Hypoglycemic Agents
210 rdf:type schema:DefinedTerm
211 Necf4cb75a6c14ebba33146fc8f41ffd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Aged
213 rdf:type schema:DefinedTerm
214 Nf316133483a245c89b661742d6c910f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Sodium-Glucose Transporter 2 Inhibitors
216 rdf:type schema:DefinedTerm
217 Nf54c5648924d48c7952a5de2eae9129b rdf:first sg:person.01232501740.42
218 rdf:rest N83cf8fdb7b6c4ad1941905346e29e079
219 Nfb9f0d31f9b34c26a418d596f8c69a91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Middle Aged
221 rdf:type schema:DefinedTerm
222 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
223 schema:name Medical and Health Sciences
224 rdf:type schema:DefinedTerm
225 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
226 schema:name Clinical Sciences
227 rdf:type schema:DefinedTerm
228 sg:journal.1096634 schema:issn 0741-238X
229 1865-8652
230 schema:name Advances in Therapy
231 schema:publisher Springer Nature
232 rdf:type schema:Periodical
233 sg:person.010035354133.81 schema:affiliation grid-institutes:None
234 schema:familyName Tuccinardi
235 schema:givenName Franco
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035354133.81
237 rdf:type schema:Person
238 sg:person.010041300312.03 schema:affiliation grid-institutes:None
239 schema:familyName Rossi
240 schema:givenName Maria C.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010041300312.03
242 rdf:type schema:Person
243 sg:person.01026702544.26 schema:affiliation grid-institutes:grid.460062.6
244 schema:familyName Candido
245 schema:givenName Riccardo
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26
247 rdf:type schema:Person
248 sg:person.01112613263.43 schema:affiliation grid-institutes:None
249 schema:familyName Nicolucci
250 schema:givenName Antonio
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112613263.43
252 rdf:type schema:Person
253 sg:person.01232501740.42 schema:affiliation grid-institutes:grid.10438.3e
254 schema:familyName Cucinotta
255 schema:givenName Domenico
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232501740.42
257 rdf:type schema:Person
258 sg:person.0637110453.18 schema:affiliation grid-institutes:None
259 schema:familyName Graziano
260 schema:givenName Giusi
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637110453.18
262 rdf:type schema:Person
263 sg:person.0642244236.63 schema:affiliation grid-institutes:None
264 schema:familyName Manicardi
265 schema:givenName Valeria
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642244236.63
267 rdf:type schema:Person
268 sg:pub.10.1007/s00125-015-3547-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048430137
269 https://doi.org/10.1007/s00125-015-3547-2
270 rdf:type schema:CreativeWork
271 sg:pub.10.1007/s00125-019-4839-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112731482
272 https://doi.org/10.1007/s00125-019-4839-8
273 rdf:type schema:CreativeWork
274 sg:pub.10.1007/s00592-014-0688-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027960230
275 https://doi.org/10.1007/s00592-014-0688-6
276 rdf:type schema:CreativeWork
277 grid-institutes:None schema:alternateName AMD Annals Coordinator, Reggio Emilia, Italy
278 CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
279 Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy
280 schema:name AMD Annals Coordinator, Reggio Emilia, Italy
281 CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
282 Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy
283 rdf:type schema:Organization
284 grid-institutes:grid.10438.3e schema:alternateName Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy
285 schema:name Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.414266.3 schema:alternateName Struttura Semplice Diabetologia e Malattie Metaboliche “Giovanni Segalini”, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy
288 schema:name Struttura Semplice Diabetologia e Malattie Metaboliche “Giovanni Segalini”, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy
289 rdf:type schema:Organization
290 grid-institutes:grid.460062.6 schema:alternateName Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
291 schema:name Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
292 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...